The Anvisa prohibited the commercialization and advertising of all cannabis products from the brand CBfarma Distribuidora de Produtos Farmacêuticos Ltda. due to lack of company operating authorization from the agency. According to the federal agency, the company does not have an Operating Authorization (AFE) to manufacture or market the items. 

What CBfarma says

In a statement, the company explained that it operates in total compliance with the resolutions regarding cannabis products, strictly following current regulatory standards.

"CBfarma Distribuidora LTDA. has never manufactured or marketed cannabis products in Brazil. We clarify that we have a pipeline of 8 products under development and in the process of being analyzed by ANVISA for future registration in the country," the company informed.

The company added: "We have already established partnerships with research institutions for the conduct of clinical studies, contributing to the advancement of the market and always prioritizing the safety, efficacy, and quality of life of patients".

Another case of irregularities from another company was already recorded in 2025

The action against irregularities in Cannabis products is not new. At the end of September, the Agency had already prohibited the sale and advertising of all items from the Forest Medical brand. On that occasion, it was found that the products were being sold without registration and that the manufacturer, Korasana, did not have operating authorization in Brazil.

In the case of Forest Medical, the companies involved claim that the information that supported Anvisa's decision is outdated. Korasana Brasil, identified as the manufacturer, distanced itself from the brand.

Check out CBfarma's full statement:

"We would like to reinforce that CBfarma operates in total compliance with ANVISA's RDCs applicable to cannabis products, strictly following all current regulatory standards.

CBfarma Distribuidora LTDA. has never manufactured or marketed cannabis products in Brazil. We clarify that we have a pipeline of 8 products under development and in the process of being analyzed by ANVISA for future registration in the country. We have already established partnerships with research institutions for the conduct of clinical studies, contributing to the advancement of the market and always prioritizing the safety, efficacy, and quality of life of patients.

We remain committed to research and development in partnership with regulatory agencies, with the aim of expanding access to quality cannabis products in Brazil, offering more safe and effective therapeutic options for patients."